Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients

Transplant Immunology

Volumn 16, Issue 1, 2006, Pages 46-51

  Schweiger, Martin ^a   Wasler, Andre ^a   Prenner, Guenther ^a   Stiegler, Philipp ^a   Stadlbauer, Vanessa ^a   Schwarz, Michaela ^a   Tscheliessnigg, Karlheinz ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cardiac transplantation; Cyclosporine A; Everolimus; Immunosuppression; Rejection

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LONG TERM CARE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 33646404334     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2006.02.001     Document Type: Article

References (25)

1. Gambino A. Challenges in heart transplantation: now and the future. Transplant Proc 35 (2003) 3069-3071
2. Valantine H. Neural use in the cardiac transplant recipients. Transplant Proc 32 S3A (2000) 27S-44S
3. Groetzner J., Meiser B., Landwehr P., et al. Mycophenolate Mofetil and Sirolimus as calcineurin inhibitor-free immunsuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 77 (2004) 568-574
4. English J., Evan A., Houghton D.C., and Bennett W.M. Cyclosporin-induced acute renal dysfunction in the rat. Evidence of ateriolar vasoconstruction with preservation of tubular function. Transplantation 44 (1987) 135
5. Busauschina A., Schnuelle P., and Van der Woude F.J. Cyclosporine nephrotoxicity. Transplant Proc 36 Suppl. 2 (2004) 229S-233S
6. Pilmore H.L., and Dittmer I.D. Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant 16 (2002) 191
7. Calne R.Y., Collier D.S., Lim S., Pollard S.G., Samaan A., White D.J., and Thiru S. Rapamycin for immunosuppressant in organ allografting. Lancet 2 (1989) 227
8. Kahan B.D., Julian B.A., Pescouitz M.D., et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 68 (1999) 1526-1532
9. Kimball P.M., Kerman R.H., and Kahan B.D. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 51 (1991) 486-490
10. Radovancevic B., El-Sabrout R., Thomas C., Radovancevic R., Frazier O.H., and Van Buren C. Rapamycin reduces rejection in heart transplant recipients. Transplant Proc 33 (2001) 3221
11. Meiser B., Reichart B., Adamidis I., Uberfuhr P., and Kaczmarek I. First experience with de-novo calcineurin inhibitor free immunosuppression following cardiac transplantation. Am J Transplant 5 (2005) 827-831
12. Eisen H.J., Tuzco E.M., Dorent R., et al. Everolimus for prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. NEJM 9 (2003) 847-858
13. Kovarik J.M., Eisen H., Dorent R., et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant 22 (2004) 1117-1125
14. Eisen H.J., and Ross H. Optimizing the immunosupressive regime in heart transplantation. J Heart Lung Transplant 23 (2004) 207-213
15. Chin C., Naftel D.C., Singh T.P., et al. Risk factors for recurrent rejection in pediatric heart transplantation: a multicenter experience. J Heart Lung Transplant 23 (2004) 178-185
16. Schuurman H.J., Cottens S., Fuchs S., et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64 (1997) 32
17. Hare J., Preeone S., and Eisen H. 48 months follow up: Everolimus in cardiac transplantation. Transpl Int 18 (2005) S1, 8
18. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimised cyclosporine dosing in renal transplant recipients: 6 month safety and efficacy results of two randomised studies. Am J Transplant 4 (2004) 626-635
19. Nashan B., Curtis J., Ponticelli C., Mourad G., Jaffe J., and Haas T. Everolimus and reduced-exposure cyclosporine in de-novo renal transplant recipients: a 3-year phase II, randomized, multicenter, open label study. Transplantation 78 (2004) 1-9
20. Eisen H.J., et al. Evaluation of cyclosporine (CsA) profiles month 2 to 6 in an international phase II randomized, multicenter, double-blind study of everolimus in de novo heart transplant recipients. J Heart Lung Transplant 24 (2005) [Abstract S89]
21. Al Aly Z., Abbas S., Moore E., Diallo O., Hauptmann P.J., Bastani B., et al. The natural history of renal function following orthotopic heart transplant. Clin Transplant 19 (2005) 683-689
22. Zuckermann A. Clinical experience with Certican (Everolimus) in maintenance heart transplant patients at the medical university of Vienna. J Heart Lung Transplant 45 (2005) S206-S209
23. Kovarik J.M., Kaplan B., Tedesco Silva H., et al. Exposure-response relationships for everolimus in de-novo kidney transplantation: defining a therapeutic range. Transplantation 73 (2002) 920
24. Lorber M., Ponticelli C., Whelchel J., et al. Therapeutic drug monitoring for everolimus in kidney transplant recipients based on exposure-efficacy and safety modelling of 12 month data. Clin Transplant 19 (2004) 145
25. Johnson M.R. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 11 (1992) S124-S132